Secukinumab: A Review in Psoriatic Arthritis

Abstract

Secukinumab (Cosentyx®) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. It is the first-in-class anti-IL-17 agent, initially approved for the treatment of plaque psoriasis, and more recently for the treatment of ankylosing spondylitis and psoriatic arthritis. This article reviews the therapeutic efficacy of subcutaneous… (More)
DOI: 10.1007/s40265-016-0602-3